Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

43%(3 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

8(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(1)

Detailed Status

Completed7

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 18 (100.0%)

Trials by Status

completed788%

withdrawn113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_1

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

NCT01862328

completedphase_1

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

NCT01814826

withdrawnphase_1

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

NCT01415765

completedphase_1

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770

completedphase_1

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

NCT00911066

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT01862328Phase 1

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Completed

NCT01814826Phase 1

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Completed

NCT01415765Phase 1

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Withdrawn

NCT02122770Phase 1

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

Completed

NCT00911066Phase 1

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Completed

NCT00722488Phase 1

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Completed

NCT01011530Phase 1

Dose Escalation Study of MLN4924 in Adults With Melanoma

Completed

NCT00677170Phase 1

Study of MLN4924 in Adult Patients With Nonhematologic Malignancies